Selective peroxisome proliferator-activated receptor δ isosteric selenium agonists as potent anti-atherogenic agents in vivo

Jungwook Chin, Jun Young Hong, Jaehwan Lee, Hoosang Hwang, Hyunsil Ko, Hyukjae Choi, Dongyup Hahn, Jaeyoung Ko, Sang Jip Nam, Jungae Tak, Jungyeob Ham, Heonjoong Kang

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

We report the synthesis and in vivo activity of a novel anti-atherogenic agent, isosteric selenium PPARδ-selective ligand. This ligand did not cause significant body or liver weight changes and did not have obvious adverse effects on intestinal polyp formation. Our overall results clearly demonstrate that PPARδ is a viable drug candidate for targeting and treating atherosclerosis.

Original languageEnglish
Pages (from-to)7239-7242
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume20
Issue number24
DOIs
StatePublished - 15 Dec 2010

Bibliographical note

Funding Information:
We are grateful to members of our laboratory. This work was supported by the Marine Biotechnology Program, Ministry of Land, Transport and Maritime Affairs (MLTM) and in part the BK21 program from Ministry of Education, Science and Technology (MEST), Korea.

Keywords

  • Anti-atherogenic agents
  • Intestinal polyp formation
  • PPARδ-selective ligand

Fingerprint

Dive into the research topics of 'Selective peroxisome proliferator-activated receptor δ isosteric selenium agonists as potent anti-atherogenic agents in vivo'. Together they form a unique fingerprint.

Cite this